Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon PlasmaCoagulation Technique
Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique (BURN)
Sponsor: Erbe USA, Incorporated
Enrolling: Male and Female Patients
IRB Number: AAAR9167
U.S. Govt. ID: NCT03621319
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to compare two types of endoscopic treatments in patients with Barretts esophagus (BE) with abnormal cells (dysplasia); radiofrequency ablation (RFA) and hybrid argon plasma coagulation (H-APC). H-APC is a newer technique in the treatment of BE and has not been adequately studied and is not approved by the FDA for routine use. This study is being conducted to better understand how H-APC works in the treatment of BE and compare it to RFA treatment.
This study is closed
Investigator
Julian Abrams, MD
Do You Qualify?
Are Are you between 18-85 years of age? Yes No
Do you have a confirmed diagnosis of Barrett's Esophagus with abnormal cells (dysplastic)? Yes No
Have you not received any prior ablative endoscopic treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE